Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help lower bad cholesterol?

NCT ID NCT05988866

Disease control Sponsor: Gaia AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial investigates whether a digital health app called Lipodia can help lower LDL (bad) cholesterol in adults with high cholesterol. Participants either use the app alongside their usual treatment or continue with usual treatment alone. The study measures cholesterol levels and other health outcomes over six months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lipodia digital health application
What this could lead to
If effective, Lipodia could offer a scalable, low-cost way to help people manage high cholesterol and reduce cardiovascular risk.
What could go wrong
This is a behavioral intervention, so results depend on user engagement. It may not work for everyone, and the study is relatively small (278 participants).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

278 people

The number who actually took part.

Started

Feb 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age ≥ 18 * Diagnosis of hypercholesterolemia (ICD-10 E78.0, E78.2, E78.4, E78.5, E78.8, E78.9) confirmed by a laboratory test and physician diagnosis * LDL-C levels above risk-adapted target * TG levels \< 400 mg/dL * Stability of potential drug treatment during the last 4 weeks * Stability of potential hormonal treatment during the last 6 months * Patient was made aware of lifestyle measures by GP or specialist * Consent to participation * Sufficient knowledge of the German language Exclusion criteria * Homozygous Familial Hypercholesterolemia (FH), given that it is a genetic condition which is relatively unresponsive to lifestyle changes * Hyperlipidemia type III, given that it is a genetic condition which is relatively unresponsive to lifestyle changes * Patients receiving plasmapheresis * Lp(a) \> 50 mg/dL * current pregnancy or planned pregnancy during the study period * planned major operations * liver dysfunction * end-stage renal failure * other systemic conditions that might interfere with successful study participation * Plans to change drug (including hormonal) treatment in the upcoming 6 months * Use of another digital intervention for hypercholesterolemia/dyslipidemia in the past

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemias are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemias Hypercholesterolemia

Contacts and locations

Locations

  • GAIA AG

    Hamburg, 22085, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.